Amgen, facing potential Enbrel price cap in Colorado, takes state's new drug affordability board to court

Amgen’s arthritis blockbuster Enbrel already owns an undesirable spot on the list of 10 drugs eligible for the first round of Medicare pricing negotiations. Now, the company is fighting back against a move in Colorado that aims to cap the med’s price at the state level.